REGISTER FOR SOSV’s VC-Founder Therapeutics Matchup July 13-17
Back
SOSV Deep Tech Live – From Bench to Boardroom: Nobel Laureate James Rothman on Cellular Logistics, Nanobiology, & VC Biotech
Back
Supriya Agarwal
Supriya Agarwal
July 13, 2026

Incremental biology is giving way to nanobiology—an era where we engineer life at the molecular scale. Today, the frontiers of human health look less like traditional pharmacology and more like advanced logistics: designing nanoscopic delivery systems, bioprinting human tissue, and controlling the traffic patterns within cells to halt everything from diabetes to viral infections.

Yet none of this would be possible without understanding the fundamental machinery that governs how cells move, package, and deliver molecules.

Join our next SOSV Deep Tech LIVE for a rare fireside chat with Professor James Rothman, Ph.D., winner of the 2013 Nobel Prize in Physiology or Medicine and Sterling Professor of Cell Biology at Yale University. Rothman’s pioneering discoveries revealed the molecular mechanisms that control transport within cells—a breakthrough that laid the foundation for modern biotechnology and helped pave the way for today’s nanobiology revolution.

Professor Rothman is one of the few scientists to have shaped both the foundations of modern biology and its commercial future. Trained as a physicist before becoming a biochemist, he currently serves as the Director of the Yale Nanobiology Institute. Beyond his landmark academic discoveries, he co-founded ARIAD Pharmaceuticals, served as Chief Scientist at GE Healthcare, and actively shapes the startup ecosystem as a board member and advisor to bleeding-edge platforms like Prellis Biologics and Celesta Capital.

He and SOSV Managing Partner Sean O’Sullivan will be digging deep into:

  • From Physics to Biology: How physical principles unlocked the mysteries of cellular transport and continue to shape the future of medicine.
  • The Bench-to-Boardroom Blueprint: The hidden bottlenecks of commercializing complex, deep-science discoveries.
  • Bioprinting and Beyond: How platform technologies are recreating human tissue in vitro to dramatically accelerate clinical timelines.
  • The Venture Capital Catalyst: What early-stage deep tech investors get wrong—and right—about backing technical founders.

Whether you’re a founder, investor, or operator, this is a chance to hear directly from one of the architects of modern biotechnology about where the field is headed and what it will take to translate breakthrough science into real-world impact.

Did you know?

Avalo.ai: An Agricultural Revolution Through AI Plant Evolution

Picture this: Acres of cotton all around you. 150,000 plants. Now, harvest them all, collect the seeds — all 45 million of them — and start sequencing genomes.

How Ten63 turned an academic project into an AI platform for drugging “undruggable” cancers

Bruce Donald, Marcel Frenkel and Mark Hallen are analyzing over 19,290,123 compounds per second at quantum accuracies to develop drugs to previously incurable cancers.

unspun’s Weaving Machines Aim to Fix Apparel’s Waste and Carbon Problem

Funded with $57 million from DCVC, Lowercarbon Capital and SOSV, among others, unspun aims to eliminate 1% of global carbon emissions

NotCo’s plant-based foods are on store shelves, but its AI engine “Giuseppe” is the real business

While it might look like a plant-based food company, NotCo is in the data and AI business—and aims to disrupt R&D in many industries that use animal and plant ingredients.

Smartex is Creating the Textile Factory of the Future

Gilberto Loureiro grew up inspecting fabrics in a Portuguese textile factory. With Smartex, he and co-founders Antonio Rocha and Paulo Ribeiro are eliminating textile defects—and their enormous cost both to manufacturers and the environment.

Novoloop Is Upcycling Your Future

Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.

Upside Foods Serves Up a Sustainable Future

To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.

Sleeping Beauty

In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.

The Loneliness of the Long-Distance Entrepreneur

In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.

Chiu Chau Reboots a Robot into a Billion Dollar Business

It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.

RxAll’s Life-Saving Deep Tech for African Pharmacies

Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.